A Case–Control Study to Evaluate Serum Lipoprotein Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis

Abstract

Background:

Studies investigating lipid abnormalities associated with psoriasis have reported conflicting results. The purpose of this study is to evaluate differences in serum lipoprotein levels among patients with psoriasis compared to controls via the use of the Vertical Auto Profile (VAP) test, which directly measures the cholesterol concentrations of all 5 lipoprotein classes and their subclasses. We also assess other cardiovascular biomarkers, including highly sensitive C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), and homocysteine.

Methods:

In this 6-year case–control study, 210 patients (110 patients with psoriasis and 100 controls) elected to participate in VAP testing between November 2009 and April 2016 at The George Washington Medical Faculty Associates dermatology clinic. All psoriatic cases were age-, sex-, and body mass index–matched to control patients. Data were analyzed in June 2016. We evaluated cardiovascular biomarkers in patients with psoriasis versus control patients and whether an association exists between the presence of psoriasis and the level of cardiovascular dysfunction.

Results:

Compared to the control group, patients with psoriasis had significantly lower high-density lipoprotein (HDL) (P = .007), HDL2 (P = .013), and HDL3 cholesterol (P = .015) as well as higher low-density lipoprotein (LDL) pattern B (P= .032), LDL3 (P = .030), and LDL4 cholesterol (P = .003). Patients with psoriasis also had lower apolipoprotein A1 (P = .011), lower Lp-PLA2 (P = .037), and higher hs-CRP (P = .048).

Conclusion:

Our findings suggest an increased risk of cardiovascular biomarker dysfunction in patients with psoriasis compared to their matched controls. Serum biomarkers such as high LDL pattern B, LDL3, and LDL4 as well as lower HDL2, HDL3, and total HDL were found to have a higher association with psoriatic disease.

Keywords

psoriasis cardiovascular disease low-density lipoprotein high-density lipoprotein apolipoprotein B lipoprotein a highly sensitive C-reactive protein

Get full access to this article

View all access options for this article.

References

Menter

Gottlieb

Feldman

. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.

Ganzetti

Campanati

Molinelli

Offidani

. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: three different diseases on a unique background. World J Cardiol. 2016;8(2):120–131. http://www.wjgnet.com/1949-8462/full/v8/i2/120.htm

Gottlieb

Chao

Dann

. Psoriasis comorbidities. J Dermatol Treat. 2008;19(1):5–21.

Isomaa

Almgren

Tuomi

. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabet Care. 2001;24(4):683–689.

Roberts

Cochet

Lamb

. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41(3):293–300. doi:10.1111/apt.13042.

Candia

Ruiz

Torres-Robles

Chávez-Tapia

Méndez Sánchez

Arrese

. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29:656–662. doi:10.1111/jdv.12847.

Van der Voort

Koehler

Dowlatshahi

. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol. 2014;70:517–524. doi:10.1016/j.jaad.2013.10.044.

Carrascosa

Rocamora

Fernandez-Torres

. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105(1):31–44. doi:10.1016/j.ad.2012.08.003.

Mehta

Gelfand

. High density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction. J Invest Dermatol. 2014;134(3):592–595.

10.

Friedewald

Cather

Gelfand

. AJC editor’s consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008:102(12):1631–1643.

11.

Mehta

Krishnamoorthy

. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224(1):218–221. doi:10.1016/j.atherosclerosis.2012.06.068.

12.

Yiu

Yeung

Zhao

. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med. 2013;273(3):273–282. doi:10.1111/ joim.12002.

13.

Sunitha

Rajappa

Thappa

. Comprehensive lipid tetrad index, atherogenic index and lipid peroxidation: surrogate markers for increased cardiovascular risk in psoriasis. Indian J Dermatol Venereol Leprol. 2015;81(5):464-471.

14.

Kulkarni

. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 2006;26(4):787–802.

15.

Rocha-Pereira

Santos-Silva

Rebelo

Figueiredo

Quintanilha

Teixeira

. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clinica Chemica Acta. 2001;303(1-2):33–39.

16.

Cakmak

Gül

Kiliç

Gönül

Soylu

Kiliç

. Homocysteine, vitamin B12, and folic acid levels in psoriasis patients. Eur Acad Dermatol Venereol. 2009;23(3):300–303.

17.

Holzer

Wolf

Curcic

. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res. 2012;53(8):1618–1624.

18.

Walldius

. The apoB/apoA-I ratio is a strong predictor of cardiovascular risk. In: Frank

Kostner

, eds. Lipoproteins—Role in Health and Diseases. Intech; 2012. doi:10.5772/47869. http://www.intechopen.com/books/lipoproteins-role-in-health-and-diseases/the-apob-apoa-i-ratio-is-a-strong-predictor-of-cardiovascular-risk. Accessed June 25, 2016.

19.

Lamarche

Tchernof

Moorjani

. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95(1):69–75.

20.

Uyanik

Ari

Onur

Gündüz

Tanülkü

Durkan

. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med. 2002;40(1):65–68.

21.

Thompson

Gao

Orfei

; Lp-PLA(2) Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375(9725):1536–1544.

22.

The Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499–2506. doi:10.1001/jama.2012.6571.

23.

Arsenault

Boekholdt

Kastelein

. Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol. 2011;8(4);197–206.

24.

Gkalpakiotis

Arebbergerova

Gkalpakioti

Potockova

Arenberger

Kraml

. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: results of a pilot study. J Dermatol. 2017;44(4):363–369.

25.

Martin

Blaha

Elshazly

. Friedewald estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62(8):732–739.

26.

Elshazly

Martin

Blaha

. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids). J Am Coll Cardiol. 2013;62(21):1960–1965.